MiNK Therapeutics, Inc. Profile Avatar - Palmy Investing

MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated dis…

Biotechnology
US, New York [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

MiNK Therapeutics, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

MiNK Therapeutics, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of MiNK Therapeutics, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of INKT's Analysis
CIK: 1840229 CUSIP: 603693102 ISIN: US6036931029 LEI: - UEI: -
Secondary Listings
INKT has no secondary listings inside our databases.